Compare USAU & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAU | ACET |
|---|---|---|
| Founded | 2014 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.8M | 111.9M |
| IPO Year | N/A | N/A |
| Metric | USAU | ACET |
|---|---|---|
| Price | $16.86 | $0.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $19.00 | $8.50 |
| AVG Volume (30 Days) | 202.9K | ★ 1.8M |
| Earning Date | 12-15-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.86 | $0.45 |
| 52 Week High | $19.20 | $1.19 |
| Indicator | USAU | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 41.96 |
| Support Level | $14.22 | $0.58 |
| Resistance Level | $17.44 | $0.70 |
| Average True Range (ATR) | 0.77 | 0.06 |
| MACD | 0.25 | 0.01 |
| Stochastic Oscillator | 82.45 | 44.56 |
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.